Evidence map›Paper›PMID 42102319›Full record

ArticleJournal of medicinal chemistry2026

Toward a Small Molecule Therapy for Angelman Syndrome: Structure-Activity Relationship Studies of 3-Aminopyrazole Phenylacetamides as Paternal

Anna Welton-Arndt, Hannah C Nourie, Hanna Vihma, Siyuan Liang, Jonathan Super, Kelin Li, Jon L Collins, Hsueh-Cheng Huang, Allison Zhang, Ashley E Trojniak and 2 more

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Anna Welton-ArndtDepartment of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Hannah C NourieDepartment of Cell Biology and Physiology, Neuroscience Center, and Carolina Institute for Developmental Disabilities, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Hanna VihmaDepartment of Cell Biology and Physiology, Neuroscience Center, and Carolina Institute for Developmental Disabilities, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.ORCID 0000-0002-6128-636X
Siyuan LiangDepartment of Cell Biology and Physiology, Neuroscience Center, and Carolina Institute for Developmental Disabilities, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Jonathan SuperDepartment of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.ORCID 0000-0002-2878-5124
Kelin LiDivision of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Jon L CollinsOffice of the Vice Chancellor for Research, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Hsueh-Cheng HuangDeerfield Discovery and Development, Deerfield Management, New York, New York 10010-1707, United States.
Allison ZhangDepartment of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Ashley E TrojniakDivision of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Benjamin D PhilpotDepartment of Cell Biology and Physiology, Neuroscience Center, and Carolina Institute for Developmental Disabilities, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.ORCID 0000-0003-2746-9143
Jeffrey AubéDepartment of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.ORCID 0000-0003-1049-5767

Funding

Small Molecule Therapeutic Discovery for Angelman SyndromeR01NS131615 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Jeffrey Aube, BENJAMIN D PHILPOT · 2023 to 2026
$2.3M
Investigating UBE3A as a driver gene in Duplication 15q syndromeR01NS129914 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BENJAMIN D PHILPOT · 2023 to 2026
$1.6M
High-speed direct detector for cryo electron microscopyS10OD032467 · OD · SCRIPPS RESEARCH INSTITUTE, THE · PI LANDER, GABRIEL C · 2022 to 2022
$600k
NIH HHS S10 OD032467NINDS NIH HHS R01 NS129914NINDS NIH HHS R01 NS131615
6 · The paper itself

Abstract

Unsilencing of paternal

Indexed as

AcetamidesAngelman SyndromePyrazolesUbiquitin-Protein LigasesAnimalsHumansMiceNeuronsStructure-Activity RelationshipAcetamidesPyrazolesUbe3a protein, mouseUbiquitin-Protein Ligases

Identifiers

PMID42102319
PMCPMC13437045

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.